July 2019
Volume 60, Issue 9
Free
ARVO Annual Meeting Abstract  |   July 2019
3D Volumetric Analysis of Vascularized Serous Pigment Epithelial Detachment Progression in Neovascular AMD using OCT Angiography
Author Affiliations & Notes
  • David Sarraf
    Ophthalmology, Stein Eye Institute UCLA, Los Angeles, California, United States
  • Adrian Au
    Ophthalmology, Stein Eye Institute UCLA, Los Angeles, California, United States
  • Kirk Kohwa Hou
    Ophthalmology, Stein Eye Institute UCLA, Los Angeles, California, United States
  • Juan Pablo Davila
    Ophthalmology, Stein Eye Institute UCLA, Los Angeles, California, United States
  • Frederic Gunnemann
    Ophthalmology, St Franziskus Hospital, Munster, Germany
  • Serena Fragiotta
    Vitreous Retina Macula NY, New York, New York, United States
  • Riccardo Sacconi
    Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy
  • Malvika Arya
    New England Eye Center, Tufts Medical Center, Boston, Massachusetts, United States
  • Daniel Pauleikhoff
    Ophthalmology, St Franziskus Hospital, Munster, Germany
  • Giuseppe Querques
    Ophthalmology, IRCCS Ospedale San Raffaele, University Vita-Salute San Raffaele, Milan, Italy
  • Nadia K Waheed
    New England Eye Center, Tufts Medical Center, Boston, Massachusetts, United States
  • K Bailey Freund
    Vitreous Retina Macula Consultants NY, New York, New York, United States
  • Srinivas R Sadda
    Ophthalmology, Doheny Eye Institute, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   David Sarraf, Amgen (C), Amgen (F), Bayer (C), Bayer (F), Genentech (C), Genentech (F), Heidelberg (F), Novartis (C), Novartis (F), Optovue (C), Optovue (F), Regeneron (F); Adrian Au, None; Kirk Hou, None; Juan Pablo Davila, None; Frederic Gunnemann, None; Serena Fragiotta, None; Riccardo Sacconi, None; Malvika Arya, None; Daniel Pauleikhoff, Bayer (R), Heidelberg (R), Novartis (R); Giuseppe Querques, None; Nadia Waheed, Apellis (C), Boehringer-Ingelheim (C), Eleven (C), Galecto (C), Genentech (C), Heidelberg (C), Janssen (C), Nidek (S), Ocudyne (C), Ocudyne (S), Optovue (S), Regeneron (C), Stealth (C), Topcon (F), Zeiss (F); K Bailey Freund, Allergan (C), Genetech (C), Genetech (F), Heidelberg (C), Novartis (C), Optovue (C), Roche (F), Zeiss (C); Srinivas Sadda, Allergan (C), Allergan (F), Carl Zeiss Meditec (F), Centervue (C), Genetech (C), Genetech (F), Heidelberg (C), Iconic (C), Novartis (C), Optos (C), Oxurion (C), Topcon (R)
  • Footnotes
    Support  Research To Prevent Blindness Inc
Investigative Ophthalmology & Visual Science July 2019, Vol.60, 2999. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      David Sarraf, Adrian Au, Kirk Kohwa Hou, Juan Pablo Davila, Frederic Gunnemann, Serena Fragiotta, Riccardo Sacconi, Malvika Arya, Daniel Pauleikhoff, Giuseppe Querques, Nadia K Waheed, K Bailey Freund, Srinivas R Sadda; 3D Volumetric Analysis of Vascularized Serous Pigment Epithelial Detachment Progression in Neovascular AMD using OCT Angiography. Invest. Ophthalmol. Vis. Sci. 2019;60(9):2999.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To analyze the evolution of type 1 neovascularization associated with vascularized serous pigment epithelial detachment (vsPED) using three-dimensional, volumetric, en-face optical coherence tomography angiography (OCTA)

Methods : Retrospective case series from four tertiary medical centers. OCTA images were analyzed at baseline, 3-, 6-, 12-, 18-, and 24-month follow-up when available. Visual acuity, interval injection history, PED maximal height and volume, and choroidal neovascularization (CNV) flow area and progression were determined at each visit. Qualitative and quantitative analysis of CNV progression and final PED morphology was performed to determine anatomical outcomes.

Results : Twenty-four eyes in twenty-two patients from four tertiary medical centers were studied. Average follow-up was 17.6 months. Across all eyes, maximum PED height decreased from 373.1μm to 317.7μm while flow area increased from 25.4% to 36.7%. Visual acuity worsened from 20/44 to 20/63. Final PED outcomes included filled fibrovascular versus persistent vascularized serous PED. Filled vsPEDs collapsed, decreased in PED height and volume, and displayed a multilayered morphology in contrast to persistent vsPEDs. Fibrovascular mulitlayered PEDs required on average seven less injections as compared to persistent vsPEDs.

Conclusions : Three dimensional, volumetric, en-face OCTA analysis of vsPED progression illustrated two anatomical outcomes: a filled, collapsed, typically multilayered fibrovascular PED versus a persistent vsPED. The filled multilayered PED displayed a reduction in PED height and volume, greater CNV flow area, and lower anti-VEGF injection burden versus the persistent vsPED and may represent a more stable anatomical outcome while the persistent vs PED may indicate a more unstable morphology.

This abstract was presented at the 2019 ARVO Annual Meeting, held in Vancouver, Canada, April 28 - May 2, 2019.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×